Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the PFS curves compared to the control arm at a ...

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. recently ...

CG Oncology thanks both Judge Rennie and the jury for their thoughtful evaluation and decisions in the case which represent a major victory for bladder cancer patients who could benefit from ...

LifeMD ® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including ...

Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 11:00 a.m. PST / 2:00 p.m. EST A live and archived webcast of the presentation will be available in the ...

Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, ...

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be ...

Beta Bionics expects to have full results from the PK-PD bridging trial in the second half of 2025, which will inform the go-forward development strategy for the glucagon candidate. Estimated total ...

Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, ...

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

Accelerates Fat Burning: Thermogenic compounds increase calorie burn, even at rest, helping to melt away stubborn belly fat. Suppresses Appetite: Reduces hunger and emotional eating—the main culprits ...

Second Quarter 2025 Financial Results: As of June 30, 2025, Cardiff Oncology had approximately $71.0 million in cash, cash equivalents, and short-term investments. Net cash used in operating ...